PriceTargets.com logo

Arcellx - ACLX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $111.87
  • Forecasted Upside: -2.31%
  • Number of Analysts: 19
  • Breakdown:
  • 1 Sell Ratings
  • 17 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$114.51 As of 03/18/2026 05:00 PM ET
▼ -0.01 (-0.01%)

This chart shows the closing price for ACLX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arcellx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACLX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACLX

Analyst Price Target is $111.87
▼ -2.31% Downside Potential
This price target is based on 19 analysts offering 12 month price targets for Arcellx in the last 3 months. The average price target is $111.87, with a high forecast of $133.00 and a low forecast of $82.00. The average price target represents a -2.31% upside from the last price of $114.51.

This chart shows the closing price for ACLX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 19 polled investment analysts is to hold stock in Arcellx. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 2 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 2 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 1 strong buy ratings
  • 14 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 2 strong buy ratings
  • 13 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
2/16/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 17 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 17 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/2/2026TD CowenDowngradeStrong-Buy ➝ Hold
2/25/2026GuggenheimDowngradeBuy ➝ Neutral$120.00 ➝ $115.00
2/24/2026UBS GroupDowngradeBuy ➝ Neutral$100.00 ➝ $115.00
2/24/2026CitigroupDowngradeBuy ➝ Neutral$110.00 ➝ $115.00
2/24/2026Leerink PartnersReiterated RatingOutperform ➝ Market Perform$115.00
2/23/2026Stifel NicolausReiterated RatingBuy ➝ Hold$127.00 ➝ $115.00
2/23/2026EvercoreSet Target$115.00
2/23/2026HC WainwrightDowngradeBuy ➝ Neutral$115.00
2/23/2026William BlairDowngradeStrong-Buy ➝ Hold
2/23/2026Canaccord Genuity GroupSet Target$115.00
2/23/2026Robert W. BairdReiterated RatingOutperform ➝ Neutral$106.00 ➝ $115.00
2/23/2026Truist FinancialDowngradeBuy ➝ Hold$134.00 ➝ $120.00
2/23/2026Leerink PartnersDowngradeStrong-Buy ➝ Hold
2/23/2026EvercoreDowngradeStrong-Buy ➝ Hold
2/23/2026Truist FinancialDowngradeBuy ➝ Hold$134.00 ➝ $120.00
2/23/2026Canaccord Genuity GroupDowngradeStrong-Buy ➝ Hold
2/23/2026Robert W. BairdDowngradeOutperform ➝ Hold$106.00 ➝ $115.00
2/23/2026Needham & Company LLCDowngradeBuy ➝ Hold
2/23/2026Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$115.00
2/12/2026Rothschild & Co RedburnDowngradeBuy ➝ Neutral$82.00
2/5/2026Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00
2/4/2026HC WainwrightReiterated RatingBuy ➝ Buy$115.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/7/2026UBS GroupInitiated CoverageBuy
1/7/2026UBS GroupInitiated CoverageBuy ➝ Buy$100.00
12/22/2025Wells Fargo & CompanyInitiated CoverageOverweight$100.00
12/22/2025Wells Fargo & CompanyInitiated CoverageOverweight$100.00
12/8/2025Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$130.00
12/8/2025Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00
11/24/2025CitigroupReiterated RatingBuy ➝ Buy
11/24/2025GuggenheimReiterated RatingBuy ➝ Buy
11/18/2025Wolfe ResearchInitiated CoveragePeer Perform
11/3/2025Canaccord Genuity GroupBoost TargetBuy ➝ Buy$121.00 ➝ $130.00
10/16/2025Stifel NicolausSet TargetBuy$129.00
10/9/2025Cantor FitzgeraldReiterated RatingNeutral$88.00
10/9/2025Cantor FitzgeraldDowngradeStrong-Buy ➝ Hold$88.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/4/2025Cantor FitzgeraldUpgradeStrong-Buy
7/31/2025ScotiabankBoost TargetSector Outperform ➝ Sector Outperform$93.00 ➝ $133.00
6/17/2025CitigroupInitiated CoverageBuy ➝ Buy$110.00
6/16/2025HC WainwrightReiterated RatingBuy ➝ Buy$115.00
5/9/2025ScotiabankLower TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.00
12/10/2024UBS GroupBoost TargetBuy ➝ Buy$106.00 ➝ $114.00
12/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$115.00 ➝ $115.00
12/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$105.00 ➝ $105.00
11/29/2024BarclaysUpgradeStrong-Buy
11/12/2024Truist FinancialBoost TargetBuy ➝ Buy$87.00 ➝ $136.00
11/8/2024Piper SandlerBoost TargetOverweight ➝ Overweight$91.00 ➝ $115.00
11/6/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$96.00 ➝ $96.00
11/6/2024HC WainwrightBoost TargetBuy ➝ Buy$80.00 ➝ $95.00
11/6/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$77.00 ➝ $106.00
11/6/2024Bank of AmericaBoost TargetBuy ➝ Buy$84.00 ➝ $100.00
11/6/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$81.00 ➝ $106.00
10/31/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$96.00 ➝ $96.00
10/18/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00 ➝ $96.00
10/18/2024Stifel NicolausBoost TargetBuy ➝ Buy$83.00 ➝ $122.00
10/17/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$85.00 ➝ $115.00
10/8/2024Rothschild & Co RedburnInitiated CoverageBuy$109.00
9/9/2024Cantor FitzgeraldReiterated RatingOverweight
9/3/2024Cantor FitzgeraldInitiated CoverageOverweight
8/9/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00 ➝ $81.00
7/22/2024Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$85.00 ➝ $85.00
6/18/2024Truist FinancialReiterated RatingBuy ➝ Buy$87.00 ➝ $87.00
5/31/2024Piper SandlerInitiated CoverageOverweight$70.00
5/15/2024Stifel NicolausBoost TargetBuy ➝ Buy$82.00 ➝ $83.00
5/14/2024EvercoreInitiated CoverageOutperform$85.00
5/13/2024EvercoreUpgradeStrong-Buy
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$82.00 ➝ $80.00
5/7/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00
4/11/2024Needham & Company LLCReiterated RatingBuy ➝ Buy$81.00
4/4/2024ScotiabankReiterated RatingOutperform$82.00
3/18/2024Needham & Company LLCBoost TargetBuy ➝ Buy$72.00 ➝ $81.00
3/14/2024Stifel NicolausReiterated RatingBuy ➝ Buy$82.00
3/7/2024Morgan StanleyInitiated CoverageOverweight$81.00
3/5/2024Truist FinancialBoost TargetBuy ➝ Buy$57.00 ➝ $87.00
2/29/2024HC WainwrightBoost TargetBuy ➝ Buy$60.00 ➝ $82.00
2/29/2024ScotiabankBoost TargetOutperform$82.00
2/29/2024Canaccord Genuity GroupBoost TargetBuy ➝ Buy$66.00 ➝ $85.00
2/29/2024BarclaysBoost TargetOverweight ➝ Overweight$62.00 ➝ $73.00
2/29/2024Robert W. BairdBoost TargetOutperform ➝ Outperform$63.00 ➝ $77.00
2/29/2024Needham & Company LLCBoost TargetBuy ➝ Buy$71.00 ➝ $72.00
1/4/2024Needham & Company LLCBoost TargetBuy ➝ Buy$65.00 ➝ $71.00
12/19/2023ScotiabankInitiated CoverageSector Outperform$66.00
12/11/2023Needham & Company LLCBoost TargetBuy ➝ Buy$60.00 ➝ $65.00
11/15/2023Needham & Company LLCBoost TargetBuy ➝ Buy$51.00 ➝ $60.00
11/15/2023HC WainwrightBoost TargetBuy ➝ Buy$50.00 ➝ $60.00
10/30/2023TD CowenInitiated CoverageOutperform
10/17/2023UBS GroupInitiated CoverageBuy$52.00
10/12/2023Leerink PartnersReiterated RatingOutperform
8/15/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$51.00
8/15/2023Stifel NicolausLower TargetBuy ➝ Buy$54.00 ➝ $52.00
8/15/2023Robert W. BairdBoost TargetOutperform ➝ Outperform$40.00 ➝ $52.00
8/15/2023HC WainwrightBoost TargetBuy ➝ Buy$49.00 ➝ $50.00
6/20/2023Truist FinancialLower Target$60.00 ➝ $57.00
6/20/2023Robert W. BairdLower Target$55.00 ➝ $40.00
5/18/2023Truist FinancialInitiated CoverageBuy$60.00
5/10/2023Bank of AmericaBoost Target$39.00 ➝ $50.00
5/9/2023Needham & Company LLCBoost Target$35.00 ➝ $51.00
5/9/2023HC WainwrightBoost Target$40.00 ➝ $49.00
5/9/2023BarclaysBoost TargetOverweight$38.00 ➝ $49.00
4/24/2023GuggenheimBoost Target$45.00 ➝ $58.00
4/19/2023Canaccord Genuity GroupBoost TargetBuy$34.00 ➝ $40.00
4/13/2023Robert W. BairdInitiated CoverageOutperform$39.00
3/30/2023HC WainwrightLower TargetBuy$42.00 ➝ $40.00
3/30/2023Leerink PartnersBoost TargetOutperform$35.00 ➝ $39.00
3/30/2023Needham & Company LLCReiterated RatingBuy$35.00
3/30/2023SVB SecuritiesBoost Target$35.00 ➝ $39.00
3/13/2023Stifel NicolausInitiated CoverageBuy$43.00
2/13/2023HC WainwrightInitiated CoverageBuy$42.00
12/13/2022Bank of AmericaReiterated RatingBuy$29.00 ➝ $37.00
12/12/2022Canaccord Genuity GroupBoost Target$32.00 ➝ $34.00
12/12/2022Needham & Company LLCBoost TargetBuy$31.00 ➝ $35.00
12/12/2022BarclaysBoost TargetOverweight$25.00 ➝ $38.00
12/9/2022Piper SandlerBoost Target$96.00 ➝ $104.00
11/24/2022Leerink PartnersLower Target$35.00
10/31/2022GuggenheimInitiated CoverageBuy$36.00
10/27/2022Needham & Company LLCInitiated CoverageBuy$31.00
7/20/2022Canaccord Genuity GroupInitiated CoverageBuy$32.00
6/23/2022Leerink PartnersLower TargetOutperform$47.00 ➝ $38.00
3/29/2022Leerink PartnersLower TargetOutperform$47.00 ➝ $44.00
3/2/2022BarclaysInitiated CoverageOverweight
3/1/2022William BlairReiterated RatingOutperform
3/1/2022Leerink PartnersInitiated CoverageOutperform$47.00
3/1/2022Bank of AmericaInitiated CoverageBuy$24.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/20/2025
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 1 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/19/2025
  • 3 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 23 very positive mentions
  • 27 positive mentions
  • 4 negative mentions
  • 3 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 23 very positive mentions
  • 27 positive mentions
  • 4 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Arcellx logo
Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $114.51
Low: $114.36
High: $114.77

50 Day Range

MA: $84.75
Low: $64.11
High: $114.52

52 Week Range

Now: $114.51
Low: $47.86
High: $114.80

Volume

2,026,058 shs

Average Volume

4,667,250 shs

Market Capitalization

$6.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.23

Frequently Asked Questions

What sell-side analysts currently cover shares of Arcellx?

The following equities research analysts have issued stock ratings on Arcellx in the last year: Canaccord Genuity Group Inc., Cantor Fitzgerald, Citigroup Inc., Evercore Inc, Guggenheim, HC Wainwright, Leerink Partners, Needham & Company LLC, Robert W. Baird, Rothschild & Co Redburn, Scotiabank, Stifel Nicolaus, TD Cowen, Truist Financial Corporation, UBS Group AG, Weiss Ratings, Wells Fargo & Company, William Blair, and Wolfe Research.
View the latest analyst ratings for ACLX.

What is the current price target for Arcellx?

0 Wall Street analysts have set twelve-month price targets for Arcellx in the last year. Their average twelve-month price target is $111.87, suggesting a possible downside of 2.3%. Scotiabank has the highest price target set, predicting ACLX will reach $133.00 in the next twelve months. Rothschild & Co Redburn has the lowest price target set, forecasting a price of $82.00 for Arcellx in the next year.
View the latest price targets for ACLX.

What is the current consensus analyst rating for Arcellx?

Arcellx currently has 1 sell rating, 17 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ACLX, but not buy more shares or sell existing shares.
View the latest ratings for ACLX.

What other companies compete with Arcellx?

Other companies that are similar to Arcellx include BioNTech, Moderna, Roivant Sciences, Revolution Medicines and Genmab A/S. Learn More about companies similar to Arcellx.

How do I contact Arcellx's investor relations team?

The company's listed phone number is 240-327-0603 and its investor relations email address is [email protected]. The official website for Arcellx is arcellx.com. Learn More about contacing Arcellx investor relations.